Puramed Bioscience Inc. is currently trading at $1.50 per share, up $0.50 or 50%, on volume of about 50,000 shares. The stock, which hit a high of $1.99 earlier today, was mentioned about six months ago – April 2, 2009 – to be exact in the FREE Daily Newsletter from QualityStocks. At the time, Puramed Bioscience’s stock was trading for only 8 cents a share! For investors who jumped aboard at that time, they have seen their holding multiply by nearly 19 times!

Puramed Bioscience engages in the research, development and marketing of non-prescription products. The company’s leading product is LipiGesic M, which provides acute relief from migraine headaches. In addition, Puramed also has plans to launch LipiGesic PM, which provides a remedy for insomnia and other sleep disorders as well as LipiGesic H for common tension headaches.

If you are an investor interested in micro-cap and small-cap stocks, such as Puramed

...

Alexza Pharmaceuticals, Inc. announced a private placement equity offering of 8.1 million shares of common stock to several qualified institutional investors. The company will receive $2.4325 per share, or approximately $19.1 million in net proceeds.

Alexza Pharmaceuticals also issued 7.3 million warrants as part of the deal. The warrants entitle the holder to purchase 0.9 shares of common stock at $2.77 per share. The warrants expire in seven years.

Alexza Pharmaceuticals is developing a proprietary drug delivery technology called the Staccato® system. This technology vaporizes unformulated pharmaceutical drugs into an aerosol form that allows rapid systemic delivery through lung inhalation.

Alexza Pharmaceuticals has completed Phase 3 trials for using this technology to deliver Loxapine for use in treating schizophrenic or bipolar disorder patients. The company plans a new drug application submission in 2010.

Staccato® is also being tested for use in other areas, including the treatment

...

Sometime during the middle of the year, Genentech (DNA) shareholders are going to get $95 in cash for each share of Genentech stock they own. In total, nearly $47 billion in funds are expected to be returned to biotechnology investors.We've come up with an effective "basket approach" to re-deploy those funds back into the biotech sector -- in search of the next Genentech.Antisense Makes a Lot of SenseFor a little over $13, investors can pick up one share of Isis Pharmaceuticals (ISIS). Isis is the market leader in antisense technology.We've made it no secret in the past -- we are big fans of antisense. We view the drug discovery engine fueled by Isis' antisense technology very similar to the power of Genentech's recombinant DNA and monoclonal antibody technology breakthroughs of the 1980's. Antisense drugs are still in their infancy, ...